GS1 Healthcare US has posted a new success story,
This morning, The Financial Express is running a front page story entitled ‘Generics Gateway ,’ by BV Mahalakshmi and Sudhir Chowdhary. While it is primarily interested in pumping up India’s emerging role in helping global pharmaceutical companies source new products, exploit new generics opportunities and secure lower-cost operations all in India, there is a much bigger story to be found...
If you’re not familiar with the American Society of Health-System Pharmacists (ASHP) — and especially if you are a pharmacist — you may want to check them out.
Okay, we continue to see bad actors in the supply chain and they continue to be . . .
Sanofi, the major pharmaceutical company based in France, has purchased a controlling interest in Shantha Biotechnics, a vaccines company based in India.
We’ve covered this topic earlier but today’s news is that pilot organizers and participants have published their findings, recommendations and conclusions in the project’s Evaluation Report. The news release about this is here. A link to the complete recommendations document is here. The bottom line is: The project team found that full supply chain traceability systems...
Everybody has their reasons for embracing, or shunning, an emerging market strategy. But if you want to know what ‘the world’s leading drug maker’ is thinking about emerging markets, and their reasons for thinking it, you’ll check out this very brief bulletin today in FinancierWorldwide featuring Jean-Michel Halfon, who runs Pfizer’s emerging market unit.